Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Korro Bio

Korro Bio (NASDAQ: KRRO) insider transactions

In the twelve months to 10 November 2026, executives and directors of Korro Bio reported 33 open-market sales of 408,779 shares ($5.7m) and 16 open-market purchases of 1,950,913 shares ($21.7m), by 17 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Korro Bio shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
26 October 2026Lynx1 Capital Management LP—Open-market purchase+25,124$11.751,624,789Form 4
23 October 2026Lynx1 Capital Management LP—Open-market purchase+2,510$12.111,599,665Form 4
22 October 2026Lynx1 Capital Management LP—Open-market purchase+12,175$9.681,557,155Form 4
22 October 2026Lynx1 Capital Management LP—Open-market purchase+40,000$11.041,597,155Form 4
14 September 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−31,888$14.12640,610Form 4
14 September 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−6,602$14.12132,650Form 4
11 September 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−8,450$13.99672,498Form 4
11 September 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−1,750$13.99139,252Form 4
11 September 2026Dolan OliverSenior Vice President, FinanceOpen-market sale−5$13.7216,241Form 4
9 September 2026Dolan OliverSenior Vice President, FinanceOpen-market sale−6$13.6016,246Form 4
8 September 2026Dolan OliverSenior Vice President, FinanceOpen-market sale−7,347$13.5116,252Form 4
26 August 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−249$13.96680,948Form 4
26 August 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−51$13.96141,002Form 4
19 August 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−23,584$14.00681,197Form 4
19 August 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−4,884$14.00141,053Form 4
11 August 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−1,775$13.96704,781Form 4
11 August 2026Formela Jean FrancoisDirectorOpen-market sale, 10b5-1 plan−368$13.96145,937Form 4
10 August 2026Lynx1 Capital Management LP—Open-market purchase+1,462$13.191,544,980Form 4
6 August 2026Lynx1 Capital Management LP—Open-market purchase+5,222$11.401,543,518Form 4
4 August 2026Aiyar RamPresident and CEOOpen-market sale−5,802$10.8469,046Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Korro Bio page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.